Financial Data and Key Metrics Changes - For the full year 2025, the company generated net income of $123.1 million, or $0.71 per share, compared to a net loss of approximately $1.4 billion in 2024 [14] - Consolidated core net income was $149.3 million or $0.86 per share, compared to core income from continuing operations of $124.3 million or $0.98 per share in 2024 [15] - Utility core net income for the year was $177.5 million compared to $180.7 million in 2024, driven by higher O&M expenses and other factors [15] Business Line Data and Key Metrics Changes - The utility's core net income decreased due to higher operational expenses, including deferred consulting and legal fees, and higher interest expenses [15] - The holding company reported a core net loss of $28.2 million, an improvement from a loss of $56.4 million in 2024, attributed to lower interest expenses and higher interest income [15] Market Data and Key Metrics Changes - The utility achieved a 37% renewable portfolio standard (RPS) in 2025, remaining on track to meet the 40% RPS requirement by 2030 [8][9] - Customer bills remained stable in 2025 despite significant investments in wildfire safety and resilience [9] Company Strategy and Development Direction - The company is focused on advancing key initiatives related to wildfire safety, legislative measures, and financial stability in the face of severe weather events [4][7] - The company plans to submit a joint rebasing proposal with Ulupono Initiative by March 6, 2026, aiming for a non-traditional rate rebasing process [10][11] - The company is pursuing low-cost financing options to reduce impacts on customers from critical investments required for safety and resilience [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the path ahead, highlighting progress made in key initiatives and the importance of resolving outstanding appeals related to the tort settlement [12][14] - The company anticipates making its first $479 million settlement payment in the second half of 2026, contingent on resolving outstanding appeals [17] Other Important Information - The company successfully issued $500 million in utility debt and increased its revolver to $600 million to support financial flexibility [8] - An executive transition is planned, with Scott DeGhetto resigning as CFO effective April 2, 2026, and Paul Ito returning to the role [12][13] Q&A Session Summary Question: What are the chances the Hawaii Supreme Court will take up the insurers' appeal? - Management noted that the only remaining item is the appeal, and previous decisions by the courts have been supportive of the settlements [21] Question: What are the latest thoughts on financing the second settlement payment? - Management indicated a preference for convertible debt for financing and stated that no financing would occur until after the settlement is approved [22][23] Question: How much of the $250 million ATM program will be used for financing? - Management stated that the ATM program is available for opportunistic use, depending on market conditions [24] Question: What is the timing for the divestment of the remaining stake in American Savings Bank? - Management confirmed plans to divest the remaining 9.9% stake in 2026, subject to market conditions [25] Question: What are the key elements in the upcoming PBR rebasing proposal? - Management highlighted the focus on inflationary adjustments, PIM redesign, and ensuring targets are within the company's control [31][32] Question: What are the milestones for the Wildfire Recovery Fund and liability cap process? - Management outlined that the PUC rulemaking process for the liability cap is expected to take 18-24 months, with critical milestones tied to this process [41][42]

Financial Data and Key Metrics Changes - For the full year 2025, the company generated net income of $123.1 million, or $0.71 per share, compared to a net loss of approximately $1.4 billion in 2024 [17] - Consolidated core net income was $149.3 million or $0.86 per share, compared to core income from continuing operations of $124.3 million or $0.98 per share in 2024 [18] - Utility core net income for the year was $177.5 million compared to $180.7 million in 2024, driven by higher O&M expenses and other factors [18] Business Line Data and Key Metrics Changes - The utility's financial performance was impacted by higher operational and maintenance expenses, primarily due to previously deferred consulting and legal fees, and higher interest expenses [18] - The holding company reported a core net loss of $28.2 million, an improvement from a loss of $56.4 million in 2024, attributed to lower interest expenses and higher interest income [18] Market Data and Key Metrics Changes - The company achieved a 37% renewable portfolio standard (RPS) in 2025, remaining on track to meet the 40% statutory RPS requirement by 2030 [10][11] - Customer bills remained stable in 2025 despite significant investments in wildfire safety and resilience [11] Company Strategy and Development Direction - The company is focused on advancing key initiatives related to wildfire safety, including the Maui wildfire tort settlement and legislative measures to support community safety [5][9] - The company plans to submit a joint rebasing proposal with Ulupono Initiative by March 6, 2026, aiming for a non-traditional rate rebasing process [12] - The company is pursuing low-cost financing options to mitigate impacts on customers from necessary investments in safety and resilience [13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting progress made in key initiatives and the importance of resolving outstanding appeals related to the tort settlement [15] - The company anticipates making its first $479 million settlement payment in the second half of 2026, contingent on resolving outstanding appeals [20] Other Important Information - The company successfully issued $500 million in utility debt and increased its revolver to $600 million, enhancing financial flexibility [10] - An executive transition is planned, with Scott DeGhetto resigning as CFO effective April 2, 2026, and Paul Ito returning to the role [15] Q&A Session Summary Question: What are the chances the Hawaii Supreme Court will take up the insurers' appeal? - Management indicated that the only remaining item is the appeal, with no briefing scheduled yet, and expressed cautious optimism based on previous supportive decisions from the courts [24] Question: What are the latest thoughts on financing the second settlement payment? - Management stated that they are leaning towards convertible debt for financing and will wait until after the settlement is approved to raise funds [25][26] Question: How much of the $250 million ATM program will be used for financing? - Management confirmed that the ATM program is available for opportunistic use, depending on market conditions [27] Question: What is the timing for the divestment of the remaining stake in American Savings Bank? - Management plans to divest the remaining 9.9% stake in 2026, subject to market conditions [28] Question: What key elements will be included in the upcoming PBR rebasing proposal? - Management highlighted the focus on inflationary adjustments, PIM redesign, and ensuring targets are achievable within their control [33][34] Question: What are the critical milestones for the Wildfire Recovery Fund and liability cap process? - Management outlined that the PUC rulemaking process for the liability cap is expected to take 18-24 months, with no immediate legislative actions planned [42][43]

Financial Data and Key Metrics Changes - For the full year 2025, the company generated net income of $123.1 million, or $0.71 per share, compared to a net loss of approximately $1.4 billion in 2024 [14] - Consolidated core net income was $149.3 million or $0.86 per share, compared to core income from continuing operations of $124.3 million or $0.98 per share in 2024 [15] - Utility core net income for the year was $177.5 million compared to $180.7 million in 2024, driven by higher O&M expenses [15] - The holding company core net loss was $28.2 million compared to $56.4 million in 2024, attributed to lower interest expense and higher interest income [15] Business Line Data and Key Metrics Changes - The utility's financial performance was impacted by higher operational and maintenance expenses, primarily due to previously deferred consulting and legal fees, and higher interest expense [15] - The company achieved a 37% renewable portfolio standard (RPS) in 2025, remaining on track to meet the 40% by 2030 statutory requirement [8] Market Data and Key Metrics Changes - The company has approximately $16 million and $486 million of unrestricted cash on hand at the holding company and utility levels, respectively [16] - The holding company has approximately $530 million in combined liquidity available under its ATM program and credit facility capacity [16] Company Strategy and Development Direction - The company is focused on advancing key initiatives post-Maui wildfires, including wildfire safety improvements and legislative measures to support community resilience [4] - The company plans to submit a joint rebasing proposal with Ulupono Initiative by March 6, 2026, aiming for a non-traditional rate rebasing process [10] - The company is pursuing low-cost financing options to reduce impacts on customers from critical investments required for safety and resilience [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the path ahead, highlighting significant progress made in 2025 and the importance of resolving outstanding appeals related to the tort settlement [12][14] - The company anticipates making its first $479 million settlement payment in the second half of 2026, contingent on resolving outstanding appeals [17] Other Important Information - The company successfully issued $500 million in utility debt last year, enhancing financial flexibility and liquidity [8] - An executive transition is planned, with Scott DeGhetto resigning as CFO effective April 2, 2026, and Paul Ito returning to the role [12] Q&A Session Summary Question: Can you discuss the latest appeal by the insurers? - Management noted that the only remaining item is the appeal regarding the summary judgment that dismissed the insurers' claims, with no briefing scheduled yet [20][21] Question: What are your thoughts on financing the second settlement payment? - Management indicated a preference for convertible debt for financing, with plans to wait until after the settlement is approved before raising funds [22][23] Question: How do you plan to use the ATM program for financing? - Management stated that the ATM program is available for opportunistic use, depending on market conditions [24] Question: What is the status of the divestment of the remaining stake in American Savings Bank? - The company intends to divest the remaining 9.9% stake in 2026, subject to market conditions [25] Question: What are the key elements in the upcoming PBR rebasing proposal? - Management highlighted the focus on inflationary adjustment factors, PIM redesign, and expanding the scope of the Exceptional Project Recovery Mechanism [30][31] Question: What are the milestones for the Wildfire Recovery Fund? - Management indicated that the PUC rulemaking process for the liability cap is expected to take 18-24 months, with critical milestones tied to this process [39][40]

Zomedica (NYSEAM:ZOM) Update Summary Company Overview - Zomedica is focused on delivering innovative diagnostic and therapeutic technologies for veterinarians, enhancing pet care and improving pet parent satisfaction. The company aims to streamline workflow, increase cash flow, and boost practice profitability for veterinary clinics [1][2]. Core Objectives - The company operates under five core objectives: 1. Improve the quality of care for pets. 2. Enhance pet parent satisfaction. 3. Improve veterinarian workflow. 4. Positively impact veterinarian cash flow. 5. Increase veterinarian profitability [2]. Research and Development (R&D) Strategy - R&D is central to Zomedica's growth, focusing on refining existing technologies and integrating new capabilities. The strategy combines acquisitions with disciplined internal development to enhance product offerings [3][4]. - The company has achieved ISO 13485 certification, ensuring high-quality development processes aligned with manufacturing standards [8]. Product Platforms TRUFORMA - The TRUFORMA platform has expanded to offer 18 assays across three species since its launch. The acquisition of Qorvo Biotechnologies has allowed Zomedica to control the full development process, accelerating timelines and reducing costs [16][17]. - Innovations include a more sensitive Feline TSH assay, which outperforms existing market standards, and enhancements to the insulin test for equine applications [19][20][21]. VetGuardian - The VetGuardian product line, introduced in 2023, has seen enhancements with the release of VetGuardian PLUS, which includes a new screen and improved internal radar for better signal quality [27][28]. - Future updates will include AI-based features aimed at enhancing non-contact vital sign monitoring [29]. TRUVIEW - The TRUVIEW platform has undergone significant transformations, improving user experience and workflow in veterinary clinics. The device now automates slide preparation and staining, enhancing the reliability of blood smear results [30][32][36]. Financial Outlook - Zomedica anticipates a positive start to Q1 2026, with expectations for revenue growth and improved margins. The company aims for profitability by the end of 2026, with a cash flow breakeven target around $55 million in revenue [43][65][72]. - The share price has remained stagnant, but the company is focused on increasing revenue and reducing operating expenses [46][60]. Market Position and Competition - Zomedica's main competitors vary by product line. For PulseVet, competitors include drugs and surgical options, while VetGuardian faces no direct competition due to its unique monitoring capabilities [75][77]. - The TRUVIEW microscope competes with devices from Zoetis and other manufacturers, but Zomedica's automated features provide a competitive edge [78][79]. Future Plans - Zomedica plans to explore human health collaborations, primarily as a technology partner rather than pursuing independent FDA approvals for human diagnostics [55][68]. - The company is also focused on expanding its product indications and enhancing its market presence in both veterinary and potential human health sectors [62][64]. Conclusion - Zomedica is committed to innovation in veterinary diagnostics and therapeutics, with a clear strategy for growth and profitability. The company is well-positioned to capitalize on its R&D advancements and market opportunities in the coming years [39].

HEI 4Q and Full Year 2025 Financial Results February 27, 2026 Non-GAAP Financial Information This presentation refers to certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles, including Core Earnings, Core Net Income and other Core measures. Reconciliations of those non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the Appendix herein. See Appendix for definition of Core Earnings and Core EPS. | 20 ...

BioXcel Therapeutics KOL Virtual Roundtable Summary Company Overview - **Company**: BioXcel Therapeutics (NasdaqCM: BTAI) - **Focus**: Development of BXCL501 for the treatment of acute agitation episodes in Alzheimer's dementia Key Industry Insights - **Alzheimer's Agitation**: There are currently no FDA-approved treatments specifically for acute agitation episodes in Alzheimer's dementia, highlighting a significant gap in care [2][11][93] - **Demographic Trends**: The Alzheimer's population is expected to double in the coming decades, with over 7 million individuals currently affected, leading to increased neuropsychiatric issues, particularly agitation [20][21] Core Points Discussed - **BXCL501 Development**: BXCL501 has shown to be well-tolerated and met its primary efficacy endpoint in a Phase 3 pivotal study for treating acute agitation in Alzheimer's dementia [3] - **Current Treatment Landscape**: Existing treatments primarily address chronic agitation, with off-label use of antipsychotics and sedatives being common, which can lead to increased risks such as sedation and falls [10][21][22][34] - **Need for Rapid Action**: BXCL501 is designed to provide rapid control of agitation, with effects seen within minutes, contrasting with existing treatments that may take days to titrate [22][23][49] Additional Important Insights - **Impact on Caregivers**: The unpredictability of agitation episodes significantly affects the quality of life for both patients and caregivers, necessitating effective management solutions [29][82] - **Potential for Home Use**: There are plans for at-home studies to evaluate the safety and efficacy of BXCL501 in non-professional settings, which could ease the burden on caregivers [47][48] - **Safety Profile**: BXCL501 has a favorable safety profile, with mild side effects reported in clinical trials, making it a viable option for older adults [49][50][56] - **Administration Method**: The sublingual film formulation of BXCL501 is seen as advantageous compared to injections, which can be distressing for patients [68][70] Market Opportunity - **Care Settings**: BXCL501 could be beneficial in various settings, including home care, assisted living, and skilled nursing facilities, helping to maintain patient independence and reduce the need for institutionalization [82][85] - **Cost Implications**: Effective management of acute agitation could potentially reduce healthcare costs associated with emergency room visits and hospitalizations [19][22][67] Conclusion - **Commitment to Innovation**: BioXcel Therapeutics is dedicated to addressing the unmet needs in the treatment of acute agitation in Alzheimer's dementia, with BXCL501 positioned as a promising solution [2][93]

Financial Data and Key Metrics Changes - The company reported normalized funds from operation (FFO) of $0.46 per diluted share for Q4 2025 and $1.72 per diluted share for the full year, representing a 22% year-over-year growth in FFO per share compared to 2024 [22][23] - Total portfolio same-store NOI growth was 11.8% in Q4 and 14.2% for the full year 2025, marking the second consecutive year of double-digit growth [10][22] - The debt to EBITDA improved by nearly a full turn in 2025, indicating a stronger financial position [22][25] Business Line Data and Key Metrics Changes - The operating portfolio, including Trilogy and SHOP segments, contributed 76.9% of consolidated cash NOI, with Trilogy's same-store NOI increasing by 14% in Q4 and 18.4% for the full year [11][12] - SHOP segment same-store NOI increased by 24.6% in Q4 and 25.2% for the full year compared to the previous year [13] - Occupancy rates for Trilogy reached 90.6% in Q4, up 275 basis points year-over-year, while SHOP also surpassed 90% occupancy [12][13] Market Data and Key Metrics Changes - The company closed over $950 million in new investments in 2025, primarily in the SHOP segment, which is now the second-largest in terms of cash NOI [16][17] - The investment pipeline remains robust with over $230 million in awarded deals, indicating strong market activity [19][60] Company Strategy and Development Direction - The company maintains a disciplined investment strategy focused on high-quality care and superior health outcomes, with no changes in capital allocation or risk management frameworks [8][21] - The emphasis on high-quality care is expected to drive demand as the aging population grows, positioning the company well for future growth [12][18] - The company is actively pursuing development projects primarily focused on Trilogy expansions, aiming for attractive yields with limited market risk [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving another year of double-digit same-store NOI growth in 2026, supported by strong occupancy levels and pricing discipline [12][13] - The leadership transition is described as seamless, with no changes in strategy, ensuring continuity in operations and execution [6][8] - The company anticipates that the demand for high-quality care will continue to grow, providing a favorable environment for its operations [12][18] Other Important Information - The company has been actively involved in off-market acquisitions, leveraging strong relationships with operators to secure favorable deals [82] - The revenue management system is being piloted with various operators, aiming to enhance pricing strategies and improve overall performance [50][51] Q&A Session Summary Question: Can you dive deeper into the acquisition environment? - The company continues to focus on higher acuity SHOP assets, which provide long-term stability [29][30] Question: Can you provide guidance on SHOP's performance? - The company expects a significant increase in pricing power as occupancy rates rise, with a conviction in future growth [35][36] Question: What are the expectations for Trilogy's occupancy and quality mix? - Trilogy's model allows for various drivers of NOI growth, with a focus on shifting to higher payor sources [39][40] Question: How is the revenue management system being rolled out? - The revenue management system is being tested with select operators, aiming to enhance their performance [50][51] Question: What is the status of the investment pipeline? - The pipeline is dynamic, with a high level of deal activity and a focus on off-market opportunities [60][61]

Financial Data and Key Metrics Changes - In 2025, Endeavour Silver produced 11 million ounces of silver equivalent metal, a 48% increase compared to 2024 [5] - The company reported record revenue of $468 million, up 115% from 2024, with cost of sales at $385 million and mine operating earnings of $83 million [7] - Cash costs increased to $19 per ounce of payable silver, primarily due to changes in the production profile [7] Business Line Data and Key Metrics Changes - In Q4 2025, Endeavour produced 2 million ounces of silver and 14,000 ounces of gold, totaling just shy of 4 million silver equivalent ounces, representing a 146% increase compared to Q4 2024 [6] - Excluding Coba and Terronera, production increased by 27% compared to the same period last year [6] Market Data and Key Metrics Changes - Silver and gold prices have seen exceptional gains, with gold trading above $5,000 and silver above $90, reflecting ongoing confidence in precious metals [4] - The company is well-positioned to benefit from current silver prices, indicating substantial runway remaining in this cycle [4] Company Strategy and Development Direction - Endeavour Silver's strategic initiatives include the acquisition of Kolpa, achieving commercial production at Terronera, and advancing the Pitarrilla development asset [4][5] - The company plans to invest $68 million in Pitarrilla in 2026, focusing on exploration and technical studies [12] Management's Comments on Operating Environment and Future Outlook - Management highlighted the impact of security events in Mexico on operations, emphasizing the safety of employees as a top priority [3] - The company anticipates a substantial reduction in direct operating costs as it transitions to liquefied natural gas in Q2 2026 [8] Other Important Information - As of December 31, 2025, the company's cash position was $215 million, providing financial strength to advance strategic initiatives [10] - The company expects to achieve improved cost efficiency at Kolpa as its plant expands to 2,500 tons per day [11] Q&A Session Summary Question: Can you discuss the mill availability and electrical interruptions at Terronera? - Management confirmed improvements in January and February, with stabilization in throughput and recovery rates [16][17] Question: What is the guidance on grades at Terronera for 2026? - Management indicated a gradual increase in grades throughout the year, with higher grades expected in the second half [24] Question: How will costs at Terronera drop in 2026? - Management expects costs to decrease as one-time expenditures are reduced and operational efficiencies are realized [56][60] Question: What changes in security protocols have been implemented at Terronera? - Management stated that while there will be increased presence around transportation lines, no dramatic changes in security costs are anticipated [65] Question: What is the status of the Bolanitos sale and its accounting impact? - The sale closed on January 15, and an accounting gain is anticipated in Q1 [70] Question: What are the permitting timelines for Pitarrilla? - Management aims for a Q1 2027 permit for the tailings storage facility, with ongoing work on engineering and permitting [84][87]

Financial Data and Key Metrics Changes - In 2025, Endeavour Silver produced 11 million ounces of silver equivalent metal, a 48% increase compared to 2024 [5] - The company reported record revenue of $468 million, up 115% from 2024, with cost of sales at $385 million and mine operating earnings of $83 million [7] - Mine operating cash flow before taxes rose by 116%, while cash costs increased to $19 per ounce of payable silver [7][8] - Adjusted net earnings for Q4 were $4.8 million, or $0.02 per share, impacted by realized losses from derivative contracts and higher financing costs [7][8] Business Line Data and Key Metrics Changes - In Q4, Endeavour Silver produced 2 million ounces of silver and 14,000 ounces of gold, totaling just shy of 4 million silver equivalent ounces, representing a 146% increase compared to Q4 of 2025 [6] - Excluding Coba and Terronera, production was up 27% compared to the same period last year [6] Market Data and Key Metrics Changes - Silver and gold prices have seen exceptional gains, with gold trading above $5,000 and silver above $90, reflecting ongoing confidence in precious metals [4] - The company is well-positioned to benefit from current silver prices, indicating substantial runway remaining in this cycle [4] Company Strategy and Development Direction - Endeavour Silver's strategic initiatives include the acquisition of Kolpa, achieving commercial production at Terronera, and advancing the Pitarrilla development asset [4][5] - The company plans to invest $68 million in Pitarrilla in 2026, including completing a feasibility study and advancing construction [12] - The focus remains on operational investment priorities across main operations and projects to drive growth in 2026 [10] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of safety and operational stability, especially in light of recent security events in Mexico [3] - The transition from diesel to liquefied natural gas is expected to significantly reduce operating costs starting in Q2 2026 [8][17] - Management expressed confidence in achieving a steady state of operations at Terronera by mid-year 2026, with expectations for improved throughput and recoveries [11][91] Other Important Information - The company raised $350 million through a convertible debt offering in December, strengthening its balance sheet [5] - As of December 31, 2025, the company's cash position was $215 million, providing financial strength for strategic initiatives [10] Q&A Session Summary Question: Updates on operational issues at Terronera - Management confirmed improvements in mill availability and electrical disruptions, with expectations to transition to LNG for better stability and cost efficiency [15][17] Question: Grade profile at Terronera - Management indicated that lower grades were due to mining lower grade stockworks initially, with expectations for higher grades in the second half of 2026 [19][23] Question: Capital spending and development at Terronera - Management acknowledged being slightly behind on development but expects costs to decrease as operations stabilize [26][28] Question: Impact of silver prices on costs - Management noted that higher silver prices would increase direct costs due to royalties and duties, but margins remain strong [41][43] Question: Derivative hedge and risk management - Management discussed the remaining gold hedge and the company's policy to remain unhedged on silver, focusing on managing exposure to currency fluctuations [48][50] Question: Accounting implications of Bolanitos sale - Management confirmed an accounting gain from the sale of Bolanitos and discussed the impact of construction costs on taxes [70][72]

Financial Data and Key Metrics Changes - The company reported normalized funds from operation (NFFO) of $0.46 per diluted share for Q4 2025 and $1.72 per diluted share for the full year, representing a 22% year-over-year growth in NFFO per share [22][23] - Total portfolio same-store NOI growth was 11.8% in Q4 and 14.2% for the full year 2025, marking the second consecutive year of double-digit growth [10][22] - The debt to EBITDA improved by nearly a full turn in 2025, with a net debt to EBITDA ratio of 3.4x [22][25] Business Line Data and Key Metrics Changes - The operating portfolio, including Trilogy and SHOP segments, contributed 76.9% of consolidated cash NOI, with Trilogy's same-store NOI increasing by 14% in Q4 and 18.4% for the full year [11][12] - SHOP segment same-store NOI increased by 24.6% in Q4 and 25.2% for the full year 2025, with occupancy surpassing 90% [13][14] - Trilogy's occupancy reached 90.6% in Q4, up 275 basis points year-over-year, supported by improved quality mix and Medicare penetration [12][13] Market Data and Key Metrics Changes - The company closed over $950 million in new investments in 2025, primarily in the SHOP segment, which is now the second-largest in terms of cash NOI [16][17] - The investment pipeline remains robust, with over $230 million in awarded deals and continued deal activity expected in 2026 [19][60] Company Strategy and Development Direction - The company maintains a disciplined healthcare investment strategy focused on high-quality care and superior health outcomes, with no changes in capital allocation or risk management frameworks [8][21] - The company is prioritizing expansions in Trilogy and campus growth initiatives, aiming for attractive incremental yields with limited market risk [21] - The focus remains on relationship-driven sourcing and disciplined underwriting to ensure long-term cash flow durability and growth [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering another year of double-digit same-store NOI growth in 2026, supported by strong occupancy levels and pricing tailwinds [12][13] - The company anticipates continued demand for high-quality operators in the aging population sector, with expectations of sustained growth in the coming years [12][18] - Management highlighted the importance of maintaining operational momentum and capital availability to capitalize on growth opportunities [25][26] Other Important Information - The company has successfully accelerated several previously announced pipeline deals, closing approximately $665 million in new acquisitions in Q4 2025 [19] - The management team emphasized the importance of high-quality care and outcomes, which have contributed to strong financial performance [15][18] Q&A Session Summary Question: Can you dive deeper into the acquisition environment? - Management noted a focus on higher acuity SHOP assets, indicating confidence in long-term stability in that asset class [29] Question: Can you provide insights on SHOP guidance and occupancy? - Management acknowledged a significant occupancy increase in SHOP but indicated that future growth may not match previous years' rates [35] Question: What is the outlook for Trilogy's occupancy and quality mix? - Management highlighted the unique model of Trilogy and the importance of shifting to higher payor sources to drive NOI growth [39] Question: How does the revenue management system rollout progress? - Management confirmed that the revenue management system is being piloted with select operators, aiming to enhance overall portfolio performance [50] Question: What is the status of the investment pipeline and expected yields? - Management indicated that current acquisitions are stabilizing in the high 5% to low 6% range, with a focus on higher quality properties [67]